170
Participants
Start Date
November 11, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
RO7247669
Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
Rigshospitalet, København Ø
Odense Universitetshospital, Onkologisk Afdeling R, Odense C
Seoul National University Bundang Hospital, Seongnam-si
Inst. Nacional de Cancerología, Mexico City
Clinica Universidad de Navarra Madrid, Madrid
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid
START Madrid. Centro Integral Oncologico Clara Campal, Madrid
Clinica Universitaria de Navarra, Pamplona
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara
Consultorio Médico Jordi Guzmán Casta, Querétaro City
National University Hospital, Singapore
National Cancer Centre, Singapore
Rabin MC, Petah Tikva
Chaim Sheba medical center, Oncology division, Ramat Gan
Hadassah University Hospital - Ein Kerem, Jerusaelm
LLC Arensia Explorer Medicine, Tbilisi
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona
Adana City Hospital, Medical Oncology, Adana
Ankara City Hospital, Ankara
Hacettepe Uni Medical Faculty Hospital, Sihhiye/Ankara
Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center, Yen?mahalle
Queen Elizabeth Hospital, Birmingham
Christie Hospital NHS Trust, Manchester
Hoffmann-La Roche
INDUSTRY